Articles related to FDA

The recent study underscores the readiness of pharmacists to dispense mifepristone following the FDA’s rule change. With basic training, nearly all participants expressed confidence in their ability to dispense this medication, highlighting your adaptability and resourcefulness.

As pharmacists, it’s crucial to note that, although these changes in FDA guidelines may not directly impact your practice, they signify a shift in how biosimilars will be identified moving forward. This could potentially influence how you advise patients about these products.

With the approval of Vabysmo, it’s a new era in the treatment of macular edema following RVO. This therapy has demonstrated comparable vision gains to aflibercept in clinical trials, offering a promising alternative for your patients.

The approval of Combogesic IV, backed by data from two phase 3 studies, signifies a major breakthrough in our ongoing efforts to provide effective and safer alternatives to opioids for postoperative pain management.

Did you know that recent court decisions could impact how we learn about drug risks? For instance, lecanemab (Leqembi), a new treatment for Alzheimer’s disease, has potential risks that are not fully disclosed in its label.

This recent development regarding survival rates in the study underscores the complexity and challenges in developing effective treatments for ALS.